about-me variable
Julius Clinical invites you to their event

Promising phase 2B trial results of Lanifibranor in NASH

About this event

NASH Webinar Series

Webinar 2 - Promising phase 2B trial results of Lanifibranor in NASH


In this webinar Prof. Sven Francque will be discussing the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH and shows promising results as treatment.

Speaker: Prof. Sven Francque

Host: Dr. Manuel Castro Cabezas

Co-host: Prof. Christophe Moreno


Audience: Clinicians, researchers, pharmaceutical industry workers, public health workers

NASH Webinar Series

This webinar is the second webinar of the NASH webinar series, each focusing on recent developments or publications on nonalcoholic steatohepatitis (NASH). The topics and publications are selected by KOLs of NASH Clinical based on relevant ground-breaking NASH research in a high-impact journal. During these webinars we offer you the opportunity to interact with original authors and experts in the NASH field.

Hosted by

  • Guest speaker
    MC G
    Manuel Castro Cabezas

  • Guest speaker
    SF G
    Sven Francque

  • Guest speaker
    CM G
    Christophe Moreno

Julius Clinical

The Science CRO

Julius Clinical is the Contract Research Organisation (CRO) that manages global clinical drug trials that will have a major impact on medicine and make a real difference to people’s lives around the world.